http://www.envita.com/conditions-we-treat/cancer/stage-4cancer/ - Stage 4 Cancer is also known as Stage IV Cancer, which spread to various sites in the body. It is a complex type of cancer to treat, and it can involve many organ systems. Envita’s vast area of technologies options gives stage 4 cancer patients the most complete approach to their cancer.

1. Relevant Stage 4 Cancer Solutions
Relevant Stage 4 Cancer Solutions
As technology and our knowledge base continues to grow, it becomes more important than ever to learn
what is present in the realm of modern-day cancer treatments – in particular, the availability of new
techniques to deal with advanced and stage 4 cancer. An article on the United States’ website
HealthReport.gov explains, "Nearly one out of two Americans born today will be diagnosed with cancer at
some point in their lifetime."
Moreover, “About 1,596,670 new cancer cases are expected to be diagnosed in 2011 - about 571,950
Americans are expected to die of cancer, more than 1,500 people a day – and cancer is the second most
common cause of death in the US, exceeded only by heart disease. In the US, cancer alone accounts for
nearly 1 of every 4 deaths," reports the *American Cancer Society.
Amid these turbulent seas, there is a powerful treatment with which to approach stage 4 cancer called
anti-angiogenic therapy. It works by starving the cancer cells from nutrients, thereby impeding its growth
and spread.
It is reported that nearly 90 percent of cancer patients succumb when their cancer metastasizes – the
calling card of stage 4 cancer. Angiogenesis is the process by which tumors grow by attracting blood
vessels to “nourish” themselves. However, a technique exists to thwart these very processes. With
newly developed modern “alternative” medicines, both metastasis and angiogenesis can be impeded or
even subjugated.
Envita leads the domestic pack by currently offering such integrative and unique processes. There is no
denying that patients benefit from an anti-angiogenic approach to supplement most traditional
chemotherapy regimes. Through rigorous tests and analysis, Envita recommends and implements

2. strategies that will work synergistically with the body to enhance the ultimate goal of patient health and
well-being.
With these great developments, it is important to give credit where credit is due. The origin of this
research field began with Judah Folkman, who realized that a tumor placed in a lab container had only a
limited potential for growth, establishing that its micro vascular network was being disrupted.
In the early days of his papers, 1964 to 1989, his findings were largely overlooked by many. While they
agreed that there was evidence of newly forming vessels, the assumption was that the smaller, weaker
cell networks were merely a side effect associated with the dying tumor cells. Eventually, Folkman could
prove that the new vessels were actually being fashioned by the cancer cells themselves as a means of
supplemental nourishment.
In hindsight, it is something of an embarrassment that Dr. Folkman was treated the way he was in the
early days of his findings. In an industry so overcome by a poor track-record, one would think that
innovators, free thinkers, and pioneers would be eagerly welcomed to the table. Unfortunately, cancer
research, like so many other fields, seems to harbor the same common pattern of contempt for the new
and unknown.
Another such example of this contemptuous foolery came when Don Ingber found that a fungus
contaminated some of his endothelial cell test samples, which caused their growth to cease. Of course,
Inber was ignored and treated like a quack, until later it was proven that angiogenesis could, in fact, be
inhibited.
Today, anti-angiogenic drugs such as sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®),
and everolimus (Afinitor®) are typically prescribed in late-stage cancers in order to impeded growth. That
being said, a simple agent like oxygen (not patentable) is an oft overlooked. To put it mildly, oxygen is
nothing less than a dominant anti-angiogenic agent. Oxygen becomes an important agent for stage 4
cancer treatment.
In fact, errors occurring in oxygen metabolism are often at the root of cancer causes as well as their
continued development. Moreover, understanding the role of oxygen and correctly administering it can
be vital for success in stage 4 cancer cases.
It is no secret that cancer cells rely upon a blood supply to spread. So, it stands to reason that
angiogenesis should be blocked to stop tumor growth. Virtually, all tumors demand an unending supply of
nutrients supplied via blood to continue to spread. Without such supplies, tumor growth is limited to a
manageable 2 mm.
In stage 4 cancer cases, it is a lack of oxygen that ultimately feeds growth and spread. The introduction of
vascular endothelial growth factor (VEGF) to angiogenesis, a critical process, actually occurs because of
hypoxia – the absence of oxygen. Transcriptional factor HIF-1 (hypoxia inducible factor 1) allows this
process to materialize.
There is always a need for hypoxic tissue on tumors to promote the release of VEGF - as they invariably
aim to grow beyond the limits of the blood supply. Should we dedicate one chemotherapy treatment to
block VEGF, we could then target ways to improve the tumor’s oxygen metabolism.

3. Tumors cannot grow or spread without VEGF. By enhancing the body’s ability to carry oxygen and
employing other cancer-killing methods simultaneously, Envita is creating new approaches to eliminate
cancer and the processes that allow for their development and growth. One secret is the ability to create
an environment that is unwelcome to stage 4 cancer cells.
And there is more good news, now that we know that precarious blood cells are an excellent way to target
cancers. Released VEGF binds to the endothelial cells of nearby vessels, and subsequently, they begin
to break up and grow in the direction of the tumor in an effort to bring new vessels to feed it. These
inferior vessels are relatively easy to detect through photodynamic protocols, which means they can be
isolated and attacked while simultaneously strengthening healthy vessels throughout the body.
Research shows that VEGF is connected with a series of tumor types, including breast, ovarian, cervical,
esophageal, lung, and cervical cancer, as well as glioblastoma multiforme and renal cell carcinoma. It
would seem that VEGF emissions may also hinder the immune system’s ability to react and fight off the
tumor - regularly occurring in stage 4 cancers.
One thing to keep in mind is that the immune system is the first and last defense against stage 4 cancer.
More than 90 percent of all cancer patients die because of metastasis, a critical component for stage 4
cancer – the very process by which cancer cells can spread into the blood supply and be dispersed
throughout the body. Sadly, many patients believe their cancer had been eradicated, only to discover
later about dormant metastasis and why cancer comes back often at stage 4. For this reason, it is
imperative to correct the body’s metabolism for oxygen and put a stop to angiogenesis.
For more information and articles on stage 4 cancer treatments, contact or visit us at Envita’s website. If
you know anyone who has been diagnosed with cancer, please forward this article to them. We welcome
you to contact us with questions and invite you to watch informative videos. You can also visit our PPMR
section to learn more about the power of Envita’s personalized medicine (link to Envita PPMR page)
for stage 4 cancer (link Envita cancer page) and chronic diseases. It is important information that may
save lives. Education is the best prescription.
Envita’s Comprehensive Smart Oncology uses the foremost of oncology in combination with aggressive
natural therapies to help a patient reach better health.
References:
*Judah Folkman <http://www.pbs.org/wgbh/nova/body/cancer-warrior.html > , <
http://en.wikipedia.org/wiki/Judah_Folkman > *Stage 4 Cancer < http://en.wikipedia.org/wiki/Stage-
4_cancer#Systems_of_staging > * Vascular endothelial growth factor
<http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor>*HealthReform.gov
<http://www.healthreform.gov/reports/fightingcancer/index.html>*American Cancer Society
<http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-
029771.pdf>